By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    photo of hands with blue veins
    8 Proven Tips on Finding Difficult Veins
    November 12, 2021
    tips for getting over the pandemic blues
    4 Proven Ways to Get Over the Pandemic Blues
    February 22, 2022
    medical industry innovations
    How is CNC Machining Transforming the Medical Industry?
    June 2, 2022
    Latest News
    Grounded Healing: A Natural Ally for Sustainable Healthcare Systems
    May 16, 2025
    Learn how to Renew your Medical Card in West Virginia
    May 16, 2025
    Choosing the Right Supplement Manufacturer for Your Brand
    May 1, 2025
    Engineering Temporary Hospitals for Extreme Weather
    April 24, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    Doctors on Google: Manhattan Research Survey 2012
    July 23, 2012
    HealthCare’s Need for Transparency Goes Far Beyond Pricing
    December 10, 2012
    Medicare Payments to Providers Are Carved, Sliced and Chopped by Sequestration
    March 25, 2013
    Latest News
    Building Smarter Care Teams: Aligning Roles, Structure, and Clinical Expertise
    May 18, 2025
    The Critical Role of Healthcare in Personal Injury Recovery: A Comprehensive Guide for Victims
    May 14, 2025
    The Backbone of Successful Trials: Clinical Data Management
    April 28, 2025
    Advancing Your Healthcare Career through Education and Specialization
    April 16, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: No More Monkeys Jumping On This Bed: Few Psych Meds Coming Our Way
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > No More Monkeys Jumping On This Bed: Few Psych Meds Coming Our Way
BusinessSpecialties

No More Monkeys Jumping On This Bed: Few Psych Meds Coming Our Way

Rhona Finkel
Last updated: June 17, 2013 7:49 am
Rhona Finkel
Share
9 Min Read
Image
SHARE

There’s nothing wrong with the size of the field.

The National Institute of Mental Health estimates that nearly one in four adults in America suffers from a diagnosable mental order in any given year.

There’s nothing wrong with the size of the field.

The National Institute of Mental Health estimates that nearly one in four adults in America suffers from a diagnosable mental order in any given year.

More Read

Is eCommerce Right for Your Health Business?
Keep in Great Shape This Winter by Staying Motivated to Run
Teamwork Improves Surgical Safety and Reduces Mortality
Factors Affecting Wound Market Growth Rates
Avoiding Accidents and Injury at the Gym

And there’s not been much to complain about the profitability of the field in past years either. Take 2009: Next Generation Pharmaceutical reports, in that year,  overall, US prescription drug sales– reached $300 billion–and psychiatric drugs made up $14.6 billion of that.

The New York Times writes that, in 2012, the fifth and sixth best-selling prescription drugs in the U.S. were Abilify and Seroquel, two  antipsychotics. Adds the Times, in 2011 alone, antipsychotics as a group were prescribed to 3.1 million Americans to the tune of $18.2 billion.Image

My how times can change in just a matter of months.

And how money flowing in can hide lack of innovative medical ideas flowing out.

For as Astra Zeneca was enjoying its intake from Seroquel, it was simultaneously preparing to shutter its lab in charge of psychiatric medications. It was not alone.

In July 2011 editorial entitled “Vanishing clinical psychopharmacology” in the  British Journal of Clinical Pharmacology, authors Gerven and Cohen point out that, in 2010, only two medications “with a broadly defined psychiatric or neurological indication” were approved by the FDA (and both had been on the market for years, for other uses). Thus there was nothing novel that year, there had been nothing novel for years previously–and the two could see nothing novel coming in the future.

Further, they noted, at the 2011 meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), there were a mere 13 (out of 300) abstracts on psychopharmacology –not one on a new drug. The world conference meeting of the Collegium Internationale Neuropsychopharmacologicum (CINP) in 2010 had 8 (out of 870) abstracts on human psychopharmacology.

And there’s worse to come.

Laura Sanders points out in ScienceNews that the process of bringing a new drug–one that deals with the brain– to market is almost excruciating in its pace.   Sanders points out that “[d]rug discovery is a tough, slow business. Initial exploratory work to identify a molecular target and a drug that will interact with that target can take years. After that, refined studies are conducted in animals, typically rodents, and then the experiment eventually moves into people. Brain drugs take about 18 years on average to go from preclinical experiments to approval.” In short, CNS (central nervous system) drugs just cost more to bring to market and take longer, according to Science magazine. And only 8% of CNS drugs that make it to clinical trials actually end up being approved–which is apparently about one-half of the success rate across all areas.

In their report in European Neuropsychopharmacology, British scientists Guy Goodwin and David Nutt add that  psychiatric Phase 2 trials can take up to four years–and then the high  failure rates of psychiatric and neurology medications, higher than for any other type of drug–kick in, often at Phase 3 or even registration. Science magazine points out that CNS drugs have a particular tendency to fail in late-stage trials.

“It’s pretty scary when you get down to it,” says Kenneth Kaitin, director of the Tufts Center for the Study of Drug Development. “These tend to be very difficult, expensive clinical trials.  Companies that endure a late-stage failure of a drug after years of testing take a huge financial hit. Very few companies can withstand that” (Sanders 2013).

Perhaps equally disturbing to the drug companies is the fact that the drugs just don’t work well enough. Thomas Insel himself, leader of the National Institute of Mental Health, makes it clear in the 2009 Journal of Clinical Investigation that he is particularly un-enthralled with antidepressants (whose rate of response, he says, is “slow and low”) and the new antipsychotics. He writes, “Remarkably, despite the heavy use of these medications, we have no evidence that the morbidity or mortality of mental disorders has dropped substantially in the past decades. . .The unfortunate reality is that current medications help too few people to get better and very few people to get well.”

And, aside from the cost of bringing the drugs to market, and aside from their. . .well. . . seeming uselessness. . .the third reason companies are gun-shy about  psychotropic medications is something major:  we just don’t understand the brain well enough.

Returning to our friends Nutt and Goodwin, they claim one of the reasons drug companies want to take their ball and go home when it comes to psychotropics is because there are ”deficiencies in the science that underpins drug discovery.”

In fact, they write, if you come right down to it, “Predictive and prognostic biomarkers for psychiatric disorders are largely non-existent.” Laura Sanders suggests that it is the brain itself that is the single largest obstruction to the successful development of new psychiatric medications.

The thing about blaming the brain? It seems utterly impervious. You can’t put a blood pressure cuff on it and measure its beats, and you sure don’t want to cut off a slice off a bipolar patient. As psychiatrist Dr. Mark Rubeinstein points out, there are “no precise biological markers, microscopic findings, or blood tests” to establish a diagnosis–so now what?

All researchers can do is collect symptoms, the outward signs of the brain’s behavior.

This is far from perfect, as sometimes one symptom matches more than one illness, or is interpreted differently by different treaters, or varies, depending on the day.

And from there, we head over to diagnosis, based on a conglomeration of these  slippery symptoms. Additionally, a person who exhibits symptoms A, B , &  D, which earn him the diagnosis of schizophrenia, may have quite a different brain composition from the woman who demonstrates C, D and F–yet, according to the Diagnostic and Statistical Manual,  she gets  termed a schizophrenic, as well. Both are treated with antipsychotics–even though their brain pathologies may be as different as it’s possible to be.

And that–apparently the drug companies thought–was just about enough of that.

So, joining hands with Astra Zeneca, which closed research facilities in both the U.S. and Europe, stopping drug-discovery work on schizophrenia, bipolar disorder, anxiety, and depression, Novartis is  working on closing its neuroscience facility, headquartered in Basel, Switzerland and GlaxoSmithKline, based in England, has closed its CNS lab entirely (saving itself  a cool $387 million).  US-based Pfizer and Merck, as well as the French company Sanofi have all significantly scaled back their research programs.

Even in the face of these closings, Dr. Insel’s concerns lay elsewhere. It’s not particularly a lab closing here or a scale-back there;  the biggest problem, says Insel, as quoted in Science, is “[t]here are very few molecular entities, very few novel ideas, and almost nothing that gives any hope for a transformation in the treatment of mental illness.”

That, Dr. Insel, is a very big problem indeed.

 

 

TAGGED:drug costspharma
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

Clinical Expertise
Building Smarter Care Teams: Aligning Roles, Structure, and Clinical Expertise
Health care
May 18, 2025
Grounded Healing: A Natural Ally for Sustainable Healthcare Systems
Grounded Healing: A Natural Ally for Sustainable Healthcare Systems
Health
May 15, 2025
Learn how to Renew your Medical Card in West Virginia
Learn how to Renew your Medical Card in West Virginia
Health
May 15, 2025
Dr. Klaus Rentrop Shares Acute Myocardial Infarction heart treatment
Dr. Klaus Rentrop Shares Acute Myocardial Infarction
Cardiology
May 13, 2025

You Might also Like

Image
Business

New WellPoint Plan Increases Healthcare Consumer’s Level of “Skin in the Game”

July 10, 2013
ACOs
Health ReformHospital Administration

ACOs and Patient Safety: Dos and Don’ts: Video

May 15, 2012
BusinesseHealthHealth ReformHospital AdministrationMedical EducationMobile HealthPublic HealthWellness

Cliff Diving for Healthcare Innovation

January 6, 2013
government and health care
BusinessFinanceHealth ReformPolicy & LawPublic Health

What Is the Best Role For Government in Health Care?

June 27, 2013
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?